Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06906627 · ClinicalTrials.gov registry record · NA
Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)
A NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by Duke University.
- Recruiting
- Registry status
- NA
- Development phase
- 750
- Enrollment target
- 6
- Study locations
NCT06906627: Recruiting NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), sponsored by Duke University.
NCT06906627 is a NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD) that is actively recruiting participants, run by Duke University. The registered enrollment target is 750 participants, above the 491-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (53% higher). The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06906627, a NA study of Type 2 Diabetes Mellitus (T2DM) and Chronic Kidney Disease (CKD), is actively recruiting participants, sponsored by Duke University.
- RECRUITING
- Registry status
- NA
- Development phase
- 750 participants
- Enrollment target
- 6
- Study locations
Study Summary
IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
Primary Outcome
Opportunity score of completion of missing guideline-recommended screening for CKD (eGFR and/or UACR) at 3 months. The opportunity score will be calculated as the ratio of the number of missing labs measured by month 3 divided by the number of missing labs at baseline.
Conditions Studied
Interventions
- OTHER (IRIS-CKD Screening Program): Home Kit
- OTHER (IRIS-CKD Screening Program): Standard Lab Order
Study Locations (6)
Alabama
- University of Alabama - Birmingham
Florida
- Orlando Health - St. Petersburg
Michigan
- University of Michigan - Ann Arbor
Minnesota
- Essentia Health - Duluth
North Carolina
- Duke University - Durham
Texas
- Baylor Scott & White - Temple
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 750 participants |
| Start Date | 2025-10-28 |
| Est. Completion | 2027-04-01 |
| Phase | NA |
What NCT06906627 shows while recruiting
NCT06906627 is an interventional study that assigns participants to a tested intervention. The registered 750 participants enrollment target is mid-sized for trials with a published cap, above the 491-participant average among 24 other Type 2 Diabetes Mellitus (T2DM) trials with a reported enrollment target (53% higher).
The record links to 3 conditions, with Type 2 Diabetes Mellitus (T2DM) appearing as the primary indexed condition, and to 2 interventions - of which (IRIS-CKD Screening Program): Home Kit is the first listed.
NCT06906627 lists 6 locations in 6 states (Alabama, Florida, Michigan).
Frequently Asked Questions
What is clinical trial NCT06906627 about?
NCT06906627 is a clinical study titled "Implementation pRogram to Improve Screening and Management for CKD in Diabetes (Program 1) (IRIS-CKD)". IRIS-CKD is an implementation study to improve guideline-recommended screening of chronic kidney disease (CKD) in individuals with type 2 diabetes (T2D) in the United States.
What is the current status of trial NCT06906627?
This trial is currently recruiting. It is a NA study. The enrollment target is 750 participants. The study started on 2025-10-28. Estimated completion is 2027-04-01.
What conditions does trial NCT06906627 study?
This clinical trial studies the following conditions: Type 2 Diabetes Mellitus (T2DM), Chronic Kidney Disease (CKD), Type 2 DM.
What interventions are being tested in trial NCT06906627?
The interventions under investigation include: (IRIS-CKD Screening Program): Home Kit (OTHER), (IRIS-CKD Screening Program): Standard Lab Order (OTHER).
Who is sponsoring clinical trial NCT06906627?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06906627 being conducted?
This trial has 6 study locations across Alabama, Florida, Michigan, Minnesota, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes Mellitus (T2DM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06906627's enrollment target sits among peer trials
750 3rd of 24 higher than 22 of 24 other Type 2 Diabetes Mellitus (T2DM) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes Mellitus (T2DM) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
CGM Adherence Compared to Finger-stick Glucose Monitoring in Pregnancies With Type 2 Pregestational Diabetes
RECRUITING · NA
-
Achieving Routine Intervention and Screening for Emotional Health
RECRUITING · NA
-
CGM for Management of Type 2 Diabetes in Pregnancy
RECRUITING · NA
-
Diabetes Electronic Prompt for Improved Care Coordination and Treatment in the ED
RECRUITING · NA
-
Continuous Glucose Monitoring for Outpatient Diabetes Management After Hospital Discharge
RECRUITING · NA
-
Diabetes Management Using Continuous Glucose Monitors and Remote Patient Monitoring in Underserved Populations
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
- NCT02087852 · 750 participants
Kidney Cancer DNA Registry
- NCT02532452 · 750 participants · Phase 2
Third Party Viral Specific T-cells (VSTs)
- NCT03126916 · 750 participants · Phase 3
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI